By Donald Zuhn –- A bill introduced in the House last July by Rep. Lloyd Doggett (D-TX) (at right), which could adversely impact pharmaceutical manufacturers holding drug patents, is starting to draw the attention of those outside the patent community. Last week, National Public Radio reported on the bill (H.R. 6505), entitled the “Medicare Negotiation and Competitive Licensing Act of 2018,” which would “require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program.” In particular, the Secretary would negotiate with pharmaceutical manufacturers the prices (including discounts, rebates, and…
View the original article here: House Bill Would Allow HHS Secretary to Authorize Competitive Licenses for Drug Patents
The article was originally posted on Patent Docs.
Each article is copyrighted to their original authors. We do not own any rights to the news or the images used. Whilst every care is taken to ensure that the news posts published are accurate, we cannot guarantee the authenticity of the news article on every occasion. There’s no copyright infringement intended. The news is for informational purposes only and does not provide legal advice.